197 related articles for article (PubMed ID: 38672512)
21. Do cannabinoids exhibit a tyramine-like effect?
Ilayan E; Feliszek M; Malinowska B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1041-6. PubMed ID: 23900610
[TBL] [Abstract][Full Text] [Related]
22. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Luca T; Di Benedetto G; Scuderi MR; Palumbo M; Clementi S; Bernardini R; Cantarella G
Eur J Pharmacol; 2009 Aug; 616(1-3):16-21. PubMed ID: 19539619
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics.
Nahler G
Pharmaceut Med; 2022 Apr; 36(2):99-129. PubMed ID: 35244889
[TBL] [Abstract][Full Text] [Related]
24. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis.
Petrosino S; Verde R; Vaia M; Allarà M; Iuvone T; Di Marzo V
J Pharmacol Exp Ther; 2018 Jun; 365(3):652-663. PubMed ID: 29632236
[TBL] [Abstract][Full Text] [Related]
25. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
26. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes.
de Almeida V; Seabra G; Reis-de-Oliveira G; Zuccoli GS; Rumin P; Fioramonte M; Smith BJ; Zuardi AW; Hallak JEC; Campos AC; Crippa JA; Martins-de-Souza D
Eur Arch Psychiatry Clin Neurosci; 2022 Oct; 272(7):1311-1323. PubMed ID: 35622101
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain.
Rangel-López E; Colín-González AL; Paz-Loyola AL; Pinzón E; Torres I; Serratos IN; Castellanos P; Wajner M; Souza DO; Santamaría A
Neuroscience; 2015 Jan; 285():97-106. PubMed ID: 25446347
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.
Giuliano M; Pellerito O; Portanova P; Calvaruso G; Santulli A; De Blasio A; Vento R; Tesoriere G
Biochimie; 2009 Apr; 91(4):457-65. PubMed ID: 19059457
[TBL] [Abstract][Full Text] [Related]
30. Exogenous delta⁹-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans.
Walter C; Ferreirós N; Bishay P; Geisslinger G; Tegeder I; Lötsch J
J Clin Psychopharmacol; 2013 Oct; 33(5):699-705. PubMed ID: 23899642
[TBL] [Abstract][Full Text] [Related]
31. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Elmes MW; Kaczocha M; Berger WT; Leung K; Ralph BP; Wang L; Sweeney JM; Miyauchi JT; Tsirka SE; Ojima I; Deutsch DG
J Biol Chem; 2015 Apr; 290(14):8711-21. PubMed ID: 25666611
[TBL] [Abstract][Full Text] [Related]
32. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
McKallip RJ; Lombard C; Fisher M; Martin BR; Ryu S; Grant S; Nagarkatti PS; Nagarkatti M
Blood; 2002 Jul; 100(2):627-34. PubMed ID: 12091357
[TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanism and Cannabinoid Pharmacology.
Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
[TBL] [Abstract][Full Text] [Related]
34. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection.
Mestre L; Correa F; Docagne F; Clemente D; Guaza C
Biochem Pharmacol; 2006 Sep; 72(7):869-80. PubMed ID: 16914119
[TBL] [Abstract][Full Text] [Related]
35. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
37. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
38. The synthetic cannabinoid WIN-55,212 induced-apoptosis in cytotrophoblasts cells by a mechanism dependent on CB1 receptor.
Almada M; Costa L; Fonseca BM; Amaral C; Teixeira N; Correia-da-Silva G
Toxicology; 2017 Jun; 385():67-73. PubMed ID: 28495606
[TBL] [Abstract][Full Text] [Related]
39. The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
Müller L; Radtke A; Decker J; Koch M; Belge G
Anticancer Res; 2017 Nov; 37(11):6341-6345. PubMed ID: 29061818
[TBL] [Abstract][Full Text] [Related]
40. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
